SPARC receives CRL from USFDA for Taclantis

12 Feb 2020 Evaluate

Sun Pharma Advanced Research Company (SPARC) has received a Complete Response Letter (CRL) from the United States Food & Drug Administration (USFDA) for the New Drug Application (NDA) for Taclantis (Paclitaxel Injection Concentrate for Suspension).

The company is reviewing the CRL and intends to work with the USFDA as soon as possible to address the concerns raised. As per the USFDA, a CRL is sent to an applicant if the agency determines that it will not approve the application or abbreviated application in its present form.

SPARC is an international pharmaceutical company engaged in research and development of drugs and  delivery systems.

Sun Pharma Adv. Res Share Price

135.10 0.65 (0.48%)
31-Dec-2025 09:50 View Price Chart
Peers
Company Name CMP
Syngene Internation. 642.50
Indegene 521.05
CMS Info Systems 340.10
Sagility 52.44
Smartworks Coworking 470.90
View more..
Register Now to get our Free Newsletter & much more!

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×